Mabs for western blotting

Tris (Dibenzylideneacetone) dipalladium (Tris DBA) was prepared by Dr Arbiser as previously described [25 (link)]. Propidium iodide (PI), RNAase and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solutions were from Sigma-Aldrich (St Louis, MO), total protein concentration was assessed by Quick Start™ Bradford dye reagent (BioRad, Hercules, CA), mAbs for Western blotting from Cell Signaling Technologies (Danvers, MA), and Annexin/PI assay from BD Biosciences (San Jose, CA). Red blood cell (RBC) lysis buffer 10 × was obtained from BioLegend (San Diego, CA). Drugs including bortezomib and carfilzomib were purchased from Selleck Chemicals (Houston, TX).

Imatinib and nilotinib were synthesized by Novartis Pharma AG, Basel, Switzerland. Compound 22 (Cpd22) [12 (link)], a tri-substituted pyrazol compound that reportedly inhibits ILK with an IC50 of 600 nM, was purchased from EMD Millipore (Billerica, MA) (Figure 1A). Compounds were initially dissolved in DMSO to make 10 mM stock solutions, and then were serially diluted to obtain final concentrations for in vitro experiments. Propidium iodide (PI), RNAase and MTT solution were purchased from Sigma-Aldrich (Saint Louis, MO), mAbs for Western blotting from Cell Signaling Technologies (Danvers, MA), and Annexin-V/PI assay from BD Biosciences (San Jose, CA).